CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 111 enrolled
Drug / intervention
Methotrexate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02366091
NCT02366091Phase 2Completed
CompareCT.gov

Inflammation and Coronary Endothelial Function in Patients With Coronary Artery Disease

Johns Hopkins University·interventional·Posted Feb 19, 2015·Updated Oct 21, 2021

In Brief

A Phase 2 clinical trial evaluating Methotrexate, Colchicine, and 1 other intervention for Coronary Artery Disease. Completed, enrolled 111 participants across 1 site.

Detailed Summary

The investigators are studying whether anti-inflammatory agents can improve abnormal coronary artery function in patients with coronary artery disease (CAD) and abnormal coronary artery endothelial function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 19, 2015
Enrollment StartJan 1, 2015
Primary CompletionAug 1, 2020
Study CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 11.4 years ago

Interventions

Methotrexatedrug

Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease

Colchicinedrug

Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.

Placebodrug

Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.